Overview

Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Status:
Completed
Trial end date:
2021-04-10
Target enrollment:
Participant gender:
Summary
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal